Veranex Appoints Megan Osorio as Chief Executive Officer

Raleigh, N.C.— [March 19, 2026] — Veranex, the industry’s first Innovation CRO (iCRO) redefining end-to-end MedTech development, today announced the appointment of Megan Osorio as Chief Executive Officer.

Osorio brings more than 25 years of global leadership experience across the medical device industry, with a proven track record of driving growth, operational transformation, and value creation across public companies, private equity–backed organizations, and high-growth businesses. Her appointment marks the beginning of a new chapter for Veranex as the company continues to scale its Innovation CRO model and help MedTech innovators bring transformative technologies to market faster and more efficiently.

Driving the Next Phase of Veranex Growth

Prior to joining Veranex, Osorio served as President and Chief Executive Officer of Resolve Surgical Technologies, where she led the company through a period of operational and cultural transformation, strengthening performance and positioning the organization for long-term growth.

Earlier in her career, she built and scaled the surgical business unit at Bioventus, creating the commercial and operational infrastructure needed to support rapid expansion and helping prepare the company for its public market debut. Through leadership roles at Johnson & Johnson, Teleflex, Bioventus, and RTI Surgical/Evergen, she developed broad expertise across surgical devices, orthobiologics, and advanced medical technologies while consistently building teams focused on innovation, execution, and patient impact.

“Megan is a transformational leader with deep MedTech expertise and a proven ability to build high-performing organizations,” said Lisa Boyle, Chief Innovation Officer and Interim CEO. “Her experience scaling businesses, integrating acquisitions, and aligning strategy with operational execution makes her uniquely positioned to lead Veranex into its next phase of growth.”

Advancing MedTech Innovation Through the iCRO Model

As Chief Executive Officer, Osorio will bring a broad industry perspective to Veranex’s integrated service model, helping ensure our teams work seamlessly across disciplines to support MedTech innovators. With the breadth of capabilities across Veranex, she is well positioned to strengthen how we collaborate and execute so clients can bring their technologies to market as efficiently and successfully as possible.

“I’m excited to join Veranex at such a pivotal moment,” said Osorio. “The company’s integrated model and deep technical expertise position it uniquely to help MedTech innovators move faster and more efficiently from idea to impact. I look forward to working with the talented Veranex team and our partners around the world to accelerate innovation that improves patient outcomes.”

About Veranex

Veranex is a global, fully integrated Innovation CRO dedicated to accelerating MedTech innovation from early concept through commercialization. Headquartered in Raleigh, N.C., and powered by more than 800 specialists worldwide, Veranex combines design & engineering, preclinical, clinical, regulatory, manufacturing, and market access expertise to deliver clarity, confidence, and speed—turning vision into velocity for device and diagnostics innovators.

For more information, visit Veranex.com